Treatment of Hemolytic Uremic Syndrome
Immediate complement blockade with eculizumab or ravulizumab is the definitive treatment for atypical HUS (aHUS) and should be initiated within 24 hours of diagnosis or strong clinical suspicion, even before genetic testing results are available, as delays directly increase morbidity and mortality. 1
Distinguishing HUS Subtypes First
Before initiating treatment, rapidly differentiate between HUS types as management differs fundamentally:
- STEC-HUS (Shiga toxin): Supportive care only—no complement blockade needed 2
- Atypical HUS (complement-mediated): Requires complement inhibition 1
- TTP: Requires plasma exchange for ADAMTS13 deficiency
Critical diagnostic step: Urgently check ADAMTS13 activity (if <10 IU/dL, it's TTP not HUS) and stool for verocytotoxin-producing E. coli 1. In children, STEC-HUS typically presents 4-5 days after diarrhea onset, whereas aHUS presents with concurrent or minimal diarrhea 1.
Treatment Algorithm for Atypical HUS
Immediate Actions (Within 24 Hours)
Start complement blockade immediately upon suspicion—do not wait for genetic confirmation. 3 The 2025 Italian consensus emphasizes that initiating treatment within 4-8 hours from diagnosis is essential, as delays are associated with increased morbidity and mortality 1.
First-line options:
- Eculizumab: Loading dose followed by maintenance dosing
- Ravulizumab: Equivalent efficacy with less frequent dosing (every 8 weeks vs every 2 weeks), improving quality of life 1, 4
Mandatory Infection Prophylaxis
Before or immediately with first dose, patients must receive:
- Quadrivalent meningococcal conjugate vaccine (A, C, W, Y)
- Meningococcal B vaccine
- Long-term antibiotic prophylaxis with penicillin (or macrolides if penicillin-allergic) for the entire duration of complement blockade 1
This is non-negotiable—complement inhibition dramatically increases invasive meningococcal disease risk.
Special Populations Requiring Modified Approach
Anti-Factor H antibody-mediated HUS: Combine eculizumab with immunosuppression (prednisone + mycophenolate mofetil). Recent evidence shows this combination allows shorter treatment duration (6 months) with excellent outcomes 5. Add rituximab if antibody titers remain persistently elevated.
Infants <1 year old: Consider non-complement genetic causes (DGKE, WT1 mutations) or metabolic disorders (MMACHC/cobalamin deficiency) 1. These may not respond to complement blockade.
Pregnancy-associated aHUS: Treat for minimum 6-12 months 3
Post-transplant aHUS: Continue until renal function recovers AND genetic variants are ruled out 3
Duration of Treatment
This is where individualization matters based on genetic risk stratification:
Minimum 6-12 months for all patients, then reassess based on:
- High-risk genetic variants (CFH, CFI, C3, CFB mutations): Consider indefinite therapy or very prolonged treatment 3
- Anti-FH antibodies: 6 months if antibodies clear with immunosuppression 5
- No identified genetic cause: Can attempt discontinuation after 6-12 months with close monitoring 3
- Triggering factors (infection, drugs, autoimmune disease): Continue until trigger resolved 3
Critical caveat: Discontinuation carries recurrence risk. Monitor closely with regular labs (CBC, creatinine, LDH, haptoglobin) after stopping therapy 1.
Alternative When Complement Blockade Unavailable
In resource-limited settings where eculizumab is inaccessible (common in developing countries):
Plasma exchange (PEX) is second-line therapy for aHUS 2. While imperfect compared to complement blockade, prompt PEX can be life-saving. For anti-FH antibody cases specifically, combine PEX with immunosuppression (steroids + mycophenolate or cyclophosphamide) 2.
STEC-HUS remains supportive only—no role for plasma therapy, antibiotics (may worsen toxin release), or complement blockade 2.
Monitoring Treatment Response
Expect hematological improvement after the second dose of eculizumab (typically within 1-2 weeks) 5. Monitor:
- Platelet count normalization
- LDH decline
- Haptoglobin recovery
- Creatinine improvement
- Resolution of hemolysis (schistocytes, hemoglobin)
Failure to respond suggests alternative diagnosis or concurrent process.
Common Pitfalls to Avoid
- Waiting for genetic results before treating: Genetic testing takes weeks; treatment must start immediately 1, 3
- Assuming absence of schistocytes excludes aHUS: Low sensitivity—don't rely on this alone 1
- Missing the diagnosis in transplant patients: 13% lack significant thrombocytopenia, 38% lack significant anemia—maintain high suspicion 1
- Forgetting meningococcal prophylaxis: This is a potentially fatal oversight with complement blockade 1
- Premature discontinuation: Minimum 6 months even with good response; recurrence can be catastrophic 3
The evidence strongly supports aggressive early complement blockade as transformative therapy that has revolutionized aHUS outcomes from a disease with high mortality and end-stage renal disease to one with excellent prognosis when treated promptly 4, 6, 7.